Table 3.
Characteristics of eyes in the three treatment groups
| Surgical Technique | AILMT * | hAM † | ART ‡ |
|---|---|---|---|
| Treated eyes | 48 | 58 | 10 |
| Age at study surgery (yr.) | 64 ± 12 | 66 ± 12 | 68 ± 11 |
| Axial length (mm) | 24.81 ± 3.08 | 26.81 ± 3.69 | 26.30 ± 2.84 |
| BCVA preop. (logMAR) | 0.95 ± 0.38†‡ | 1.21 ± 0.45*‡ | 1.59 ± 0.66*† |
| FTMH min. diameter (μm) | 551 ± 215 | 684 ± 273 | 881 ± 514*† |
| FTMH bas. diameter (μm) | 801 ± 413 | 1058 ± 386 | 1101 ± 469 |
| Previous surgeries (mean) | 1.0 | 1.1 | 0.8 |
| Tamponade (Oil–Gas–Air) | 2—46—0 | 3—40—15 | 7 – 3—0 |
| Face positioning (days) | 5.2 | 4.6 | 4.9 |
| BCVA final (logMAR) | 0.70 ± 0.47 | 0.70 ± 0.34 | 1.59 ± 0.86*† |
| FTMH closed | 43 (90%) | 54 (93%) | 10 (100%) |
Each surgical group has an identifying symbol: * for the autologous internal limiting membrane free flap transplantation (AILMT) group; † for the human amniotic membrane (hAM) group; ‡ for the autologous retinal graft transplantation (ART) group. The presence of one or two symbols next to a value in the three-column format marks the significant difference with respect to the group/s identified by the symbol/s
BCVA: best-corrected visual acuity; FTMH: full thickness macular hole; min. diameter: minimum diameter; bas. diameter: basal diameter